HDAC2 IHC tracks shorter PSA relapse in prostate cancer
In 192 prostate carcinomas, class I HDACs were often strongly expressed; HDAC2 independently predicted shorter PSA relapse and linked to dedifferentiation/proliferation.
Source
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
Study at a glance
- Design
- Cohort — IHC scoring of HDAC1/2/3 with PSA-relapse follow-up
- N
- N=192 · Prostate carcinomas scored by immunohistochemistry
- Population
- Patients with prostate carcinoma assessed for HDAC expression
- Outcome
- HDAC expression associations with clinicopathology, proliferation, and PSA relapse
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Authors scored HDAC1/2/3 immunohistochemistry in 192 prostate carcinomas and correlated expression with clinicopathological features, proliferation, and PSA-relapse follow-up.
What they found
Strong expression was common (HDAC1 69.8%, HDAC2 74%, HDAC3 94.8%). High HDAC1/2 associated with dedifferentiation; strong HDAC expression tracked higher proliferation. HDAC2 was an independent prognostic marker associated with shorter PSA relapse.
The limits
What it doesn't show
Prognostic IHC is not proof that HDAC inhibitors improve outcomes in this cohort. PSA relapse is a surrogate, not metastasis-free or prostate-cancer–specific survival alone. Isoform differences matter for inhibitor interpretation.
Key terms
- Class I HDACs
- HDAC1, HDAC2, and HDAC3 — nuclear deacetylases scored by IHC here.
- PSA relapse
- Persistent PSA rise from nadir after treatment — progression surrogate linked to HDAC2.
- Independent prognostic marker
- HDAC2 retained prognostic value after clinicopathological adjustment in this cohort.
- Dedifferentiation
- Higher-grade tumour features associated with high HDAC1/HDAC2 rates.
- Immunohistochemistry
- Tissue protein staining used to score HDAC isoform expression.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
Independent prognostic HDAC isoform here?
Common questions
How many tumours were stained?
192 prostate carcinomas.
How common was strong HDAC staining?
HDAC1 69.8%, HDAC2 74%, HDAC3 94.8% scored high/strong.
Which isoform was independently prognostic?
HDAC2 — linked to shorter PSA relapse.
What else tracked high HDAC expression?
Tumour dedifferentiation (HDAC1/2) and enhanced proliferation (all three).
Does this approve an HDAC inhibitor?
No — it supports isoform biology and prognosis; drug benefit needs trials.
More on Oncology outcomes